A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
收藏DataCite Commons2025-12-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012120/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
提供机构：
Vivli
创建时间：
2025-12-10
